170 related articles for article (PubMed ID: 37178706)
1. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson AL; Zaman K; Hoque M; Estivariz CF; Burns CC; Konopka-Anstadt JL; Mainou BA; Kovacs SD; An Q; Lickness JS; Yunus M; Snider CJ; Zhang Y; Coffee E; Abid T; Wassilak SGF; Pallansch MA; Oberste MS; Vertefeuille JF; Anand A
Lancet Infect Dis; 2023 Sep; 23(9):1062-1071. PubMed ID: 37178706
[TBL] [Abstract][Full Text] [Related]
2. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.
Rivera Mejía L; Peña Méndez L; Bandyopadhyay AS; Gast C; Mazara S; Rodriguez K; Rosario N; Zhang Y; Mainou BA; Jimeno J; Aguirre G; Rüttimann R
Lancet Infect Dis; 2024 Mar; 24(3):275-284. PubMed ID: 38109921
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.
Zaman K; Bandyopadhyay AS; Hoque M; Gast C; Yunus M; Jamil KM; Mainou BA; Konopka-Anstadt JL; Hendley WS; Vincent A; Clemens R; Clemens SAC; Ross AG; Clemens JD; Tritama E
Lancet; 2023 Jan; 401(10371):131-139. PubMed ID: 36495882
[TBL] [Abstract][Full Text] [Related]
6. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.
Zaman K; Estívariz CF; Morales M; Yunus M; Snider CJ; Gary HE; Weldon WC; Oberste MS; Wassilak SG; Pallansch MA; Anand A
Lancet Infect Dis; 2018 Jun; 18(6):657-665. PubMed ID: 29571817
[TBL] [Abstract][Full Text] [Related]
10. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Ochoge M; Futa AC; Umesi A; Affleck L; Kotei L; Daffeh B; Saidy-Jah E; Njie A; Oyadiran O; Edem B; Jallow M; Jallow E; Donkor SA; Tritama E; Abid T; Jones KAV; Mainou BA; Konz JO; Fix A; Gast C; Clarke E
Lancet; 2024 Mar; 403(10432):1164-1175. PubMed ID: 38402887
[TBL] [Abstract][Full Text] [Related]
11. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
Snider CJ; Zaman K; Estivariz CF; Yunus M; Weldon WC; Wannemuehler KA; Oberste MS; Pallansch MA; Wassilak SG; Bari TIA; Anand A
Lancet; 2019 Jun; 393(10191):2624-2634. PubMed ID: 31104832
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
14. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.
Mir F; Quadri F; Mach O; Ahmed I; Bhatti Z; Khan A; Rehman NU; Durry E; Salama M; Oberste SM; Weldon WC; Sutter RW; Zaidi AK
Lancet Infect Dis; 2015 Aug; 15(8):889-97. PubMed ID: 26093979
[TBL] [Abstract][Full Text] [Related]
15. Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
Snider CJ; Zaman K; Wilkinson AL; Binte Aziz A; Yunus M; Haque W; Jones KAV; Wei L; Estivariz CF; Konopka-Anstadt JL; Mainou BA; Patel JC; Lickness JS; Pallansch MA; Wassilak SGF; Steven Oberste M; Anand A
Vaccine; 2023 Sep; 41(41):6083-6092. PubMed ID: 37652822
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X
Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
